Ex-Abbott reps sue for overtime wages

Share this article:

Two former Abbott Laboratories sales reps have sued the company in federal court in Chicago, claiming the drugmaker denied them overtime wages.


The lawsuit, which seeks class-action status, comes on the heels of similar lawsuits filed last year by reps against other pharmaceutical companies including AstraZeneca, Eli Lilly, Johnson & Johnson and Pfizer.


The lawsuit argues that Abbott classifies its reps as exempt under the federal Fair Labor Standards Act, meaning they are not entitled to receive overtime pay.


Under current federal labor laws, sales forces can be exempt from overtime wages. But attorneys for the plaintiffs in the case argue that drug reps often work up to 70 hours a week and should not be classified as sales people.


“Although the companies claim that the representatives are salespersons and therefore not protected by overtime laws, with some exceptions, they actually don’t sell anything,” said attorney Charles Joseph of Joseph & Herzfeld, who filed the lawsuit on behalf of the former Abbott employees. “Rather, they are tasked to influence the prescribing behaviors of doctors.”


The lawsuit is asking the court to order Abbott to start paying overtime to its pharmaceutical reps and seeks compensation to current and former employees denied overtime pay.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...